INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uncomplicated Plasmodium Falciparum Malaria
Conditions
Uncomplicated Plasmodium Falciparum Malaria
Trial Timeline
Jan 23, 2024 → Jun 23, 2026
NCT ID
NCT05750628About INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156
INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 is a phase 2 stage product being developed by Novartis for Uncomplicated Plasmodium Falciparum Malaria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05750628. Target conditions include Uncomplicated Plasmodium Falciparum Malaria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05750628 | Phase 2 | Recruiting |
Competing Products
13 competing products in Uncomplicated Plasmodium Falciparum Malaria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZY19489 + Ferroquine (FQ) + Placebo | Zydus Lifesciences | Phase 1 | 33 |
| KLU156 + Coartem | Novartis | Phase 3 | 77 |
| Artemether-lumefantrine (COA566) | Novartis | Phase 2/3 | 65 |
| INE963 | Novartis | Phase 2 | 52 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 52 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 52 |
| Co-artemether | Novartis | Approved | 85 |
| Broncho-munal® + Placebo | Sandoz Group | Phase 3 | 74 |
| Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg | Amneal Pharmaceuticals | Phase 3 | 72 |
| Peramivir + Placebo | BioCryst Pharmaceuticals | Phase 2 | 47 |
| solithromycin + ceftriaxone + azithromycin | Allergy Therapeutics | Phase 3 | 72 |
| Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin | Iterum Therapeutics | Phase 3 | 69 |